keyword
MENU ▼
Read by QxMD icon Read
search

CALGB

keyword
https://www.readbyqxmd.com/read/28327908/predicted-vitamin-d-status-and-colon-cancer-recurrence-and-mortality-in-calgb-89803-alliance
#1
M A Fuchs, C Yuan, K Sato, D Niedzwiecki, X Ye, L B Saltz, R J Mayer, R B Mowat, R Whittom, A Hantel, A Benson, D Atienza, M Messino, H Kindler, A Venook, F Innocenti, R S Warren, M M Bertagnolli, S Ogino, E L Giovannucci, E Horvath, J A Meyerhardt, K Ng
Background: HASH(0x49a5938) Observational studies suggest that higher levels of 25-hydroxyvitamin D 3 (25(OH)D) are associated with a reduced risk of colorectal cancer and improved survival of colorectal cancer patients. However, the influence of vitamin D status on cancer recurrence and survival of patients with stage III colon cancer is unknown. Patients and methods: HASH(0x417c608) We prospectively examined the influence of post-diagnosis predicted plasma 25(OH)D on outcome among 1,016 patients with stage III colon cancer who were enrolled in a National Cancer Institute-sponsored adjuvant therapy trial (CALGB 89803)...
March 15, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28283904/using-eprognosis-to-estimate-2-year-all-cause-mortality-in-older-women-with-breast-cancer-cancer-and-leukemia-group-b-calgb-49907-and-369901-alliance-a151503
#2
Gretchen G Kimmick, Brittny Major, Jonathan Clapp, Jeff Sloan, Brandelyn Pitcher, Karla Ballman, Myra Barginear, Rachel A Freedman, Andrew Artz, Heidi D Klepin, Jacqueline M Lafky, Judith Hopkins, Eric Winer, Clifford Hudis, Hyman Muss, Harvey Cohen, Aminah Jatoi, Arti Hurria, Jeanne Mandelblatt
PURPOSE: Tools to estimate survival, such as ePrognosis ( http://eprognosis.ucsf.edu/carey2.php ), were developed for general, not cancer, populations. In older patients with breast cancer, accurate overall survival estimates would facilitate discussions about adjuvant therapies. METHODS: Secondary analyses were performed of data from two parallel breast cancer studies (CALGB/Alliance 49907/NCT000224102 and CALGB/Alliance 369901/NCT00068328). We included patients (n = 971) who were age 70 years and older with complete baseline quality of life data (194 from 49907; 777 from 369901)...
March 10, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28274562/biopsy-first-lessons-learned-from-cancer-and-leukemia-group-b-calgb-140503
#3
Leslie J Kohman, Lin Gu, Nasser Altorki, Ernest Scalzetti, Linda J Veit, Jason M Wallen, Xiaofei Wang
OBJECTIVE: Cancer and Leukemia Group B 140503 is an ongoing, multicenter randomized trial assessing whether sublobar resection is equivalent to lobectomy for the treatment of stage I A non-small cell lung cancer (NSCLC) ≤2 cm in diameter. The objective of this report is to determine the reasons precluding intraoperative randomization. METHODS: From June 15, 2007, to March 22, 2013, 637 patients were preregistered to the trial. Three hundred eighty-nine were randomized successfully (61%), and 248 patients were not randomized (39%)...
February 7, 2017: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28219113/personality-coping-and-social-support-as-predictors-of-long-term-quality-of-life-trajectories-in-older-breast-cancer-survivors-calgb-protocol-369901-alliance
#4
Estrella Durá-Ferrandis, Jeanne S Mandelblatt, Jonathan Clapp, George Luta, Leigh Anne Faul, Gretchen Kimmick, Harvey J Cohen, Rachel L Yung, Arti Hurria
OBJECTIVE: To determine long-term quality-of-life (QoL) trajectories among breast cancer survivors aged 65+ ("older") evaluating the effects of personality and social support. METHODS: Older women (N = 1280) newly diagnosed with invasive, non-metastatic breast cancer completed baseline assessments. Follow-up data were collected 6 and 12 months later and then annually for up to 7 years (median 4.5 years). QoL was assessed using EORTC-QLQC30 emotional, physical, and cognitive scales...
February 20, 2017: Psycho-oncology
https://www.readbyqxmd.com/read/28161554/maintenance-sunitinib-following-initial-platinum-based-combination-chemotherapy-in-advanced-stage-iiib-iv-non-small-cell-lung-cancer-a%C3%A2-randomized-double-blind-placebo-controlled-phase-iii-study-calgb-30607-alliance
#5
Maria Q Baggstrom, Mark A Socinski, Xiaofei F Wang, Lin Gu, Thomas E Stinchcombe, Martin J Edelman, Sherman Baker, Josephine Feliciano, Paul Novotny, Olwen Hahn, Jeffrey A Crawford, Everett E Vokes
INTRODUCTION: The aim of this study was to evaluate efficacy of maintenance sunitinib after first-line chemotherapy for stage IIIB/IV NSCLC. METHODS: Cancer and Leukemia Group B 30607 trial was a randomized, double-blind, placebo-controlled, phase III study that enrolled patients without progression after four cycles of first-line platinum-based doublet chemotherapy with or without bevacizumab. Bevacizumab was allowed only during the four cycles of chemotherapy...
February 1, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28137741/pd-l1-protein-expression-assessed-by-immunohistochemistry-is-neither-prognostic-nor-predictive-of-benefit-from-adjuvant-chemotherapy-in-resected-non-small-cell-lung-cancer
#6
M-S Tsao, G Le Teuff, F A Shepherd, C Landais, P Hainaut, M Filipits, R Pirker, T Le Chevalier, S Graziano, R Kratze, J-C Soria, J-P Pignon, L Seymour, E Brambilla
BACKGROUND: The expression of programmed death (PD) ligand 1 (PD-L1) protein expression assessed by immunohistochemistry (IHC) has been correlated with response and survival benefit from anti-PD-1/PD-L1 immune checkpoint inhibitor therapies in advanced non-small cell lung carcinoma (NSCLC). The efficacy of several agents appears correlated with PD-L1 expression. It remains controversial whether PD-L1 is prognostic in NSCLC. We assessed the prognostic value of PD-L1 IHC and its predictive role for adjuvant chemotherapy in early stage NSCLC...
January 30, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28089784/axillary-management-of-stage-ii-iii-breast-cancer-in-patients-treated-with-neoadjuvant-systemic-therapy-results-of-calgb-40601-her2-positive-and-calgb-40603-triple-negative
#7
David W Ollila, Constance T Cirrincione, Donald A Berry, Lisa A Carey, William M Sikov, Clifford A Hudis, Eric P Winer, Mehra Golshan
BACKGROUND: Management of the axilla in stage II/III breast cancer undergoing neoadjuvant systemic therapy (NST) is controversial. To understand current patterns of care, we collected axillary data from 2 NST trials: HER2-positive (Cancer and Leukemia Group B [CALGB] 40601) and triple-negative (CALGB 40603). STUDY DESIGN: Axillary evaluation pre- and post-NST was per the treating surgeon and could include sentinel node biopsy. Post-NST, node-positive patients were recommended to undergo axillary lymph node dissection (ALND)...
January 13, 2017: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/28007623/small-cell-lung-cancer-exhibits-frequent-inactivating-mutations-in-the-histone-methyltransferase-kmt2d-mll2-calgb-151111-alliance
#8
Arnaud Augert, Qing Zhang, Breanna Bates, Min Cui, Xiaofei Wang, Gary Wildey, Afshin Dowlati, David MacPherson
INTRODUCTION: SCLC is a lethal neuroendocrine tumor type that is highly prone to metastasis. There is an urgency to understand the mutated genes that promote SCLC, as there are no approved targeted therapies yet available. SCLC is rarely resected, limiting the number of samples available for genomic analyses of somatic mutations. METHODS: To identify potential driver mutations in human SCLC we sequenced the whole exomes of 18 primary SCLCs and seven cell lines along with matched normal controls...
December 19, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27972465/bevacizumab-in-the-treatment-of-kras-wild-type-metastatic-colorectal-cancer-an-economic-analysis-based-on-the-calgb-80405-trial
#9
C Silva, I Monteiro, C Tournier
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27967294/patterns-of-growth-factor-usage-and-febrile-neutropenia-among-older-patients-with-diffuse-large-b-cell-non-hodgkin-lymphoma-treated-with-chop-or-r-chop-the-intergroup-experience-calgb-9793-ecog-swog-4494
#10
Vicki A Morrison, Edie A Weller, Thomas M Habermann, Shuli Li, Richard I Fisher, Bruce D Cheson, Bruce A Peterson
Patterns of myeloid growth factor (GF) usage and febrile neutropenia (FN) were examined in patients >60 years of age with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) enrolled on CALGB 9793/ECOG-SWOG 4494, receiving initial therapy with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or rituximab + CHOP (R-CHOP). Myeloid GFs were administered to 256/520 (49%) patients. Indications for use were: prevent dose reduction/dose delay (81%, 207/256); treat FN or non-febrile neutropenia (NFN) (19%, 48/256)...
August 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27907852/the-relevance-of-primary-tumour-location-in-patients-with-metastatic-colorectal-cancer-a-meta-analysis-of-first-line-clinical-trials
#11
Julian Walter Holch, Ingrid Ricard, Sebastian Stintzing, Dominik Paul Modest, Volker Heinemann
BACKGROUND: Retrospective subgroup analyses suggest that primary tumour location (PTL) has a prognostic importance and relates to response to targeted therapy. METHODS: We conducted a meta-analysis of first-line clinical trials available up to October 2016, which assessed the relevance of PTL in patients with metastatic colorectal cancer (mCRC). Right- and left-sided colorectal cancers were differentiated (RC and LC). RESULTS: In 13 first-line randomised controlled trials and one prospective pharmacogenetic study, RC was associated with a significantly worse prognosis compared with LC (hazard ratio [HR] for overall survival: 1...
January 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/27866278/risk-of-acute-myeloid-leukemia-and-myelodysplastic-syndrome-among-older-women-receiving-anthracycline-based-adjuvant-chemotherapy-for-breast-cancer-on-modern-cooperative-group-trials-alliance-a151511
#12
Rachel A Freedman, D K Seisler, J C Foster, J A Sloan, J M Lafky, G G Kimmick, A Hurria, H J Cohen, E P Winer, C A Hudis, A H Partridge, L A Carey, A Jatoi, H D Klepin, M Citron, D A Berry, L N Shulman, A U Buzdar, V J Suman, H B Muss
PURPOSE: We examined acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) events among 9679 women treated for breast cancer on four adjuvant Alliance for Clinical Trials in Oncology trials with >90 months of follow-up in order to better characterize the risk for AML/MDS in older patients receiving anthracyclines. METHODS: We used multivariable Cox regression to examine factors associated with AML/MDS, adjusting for age (≥65 vs. <65 years; separately for ≥70 vs...
January 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27704226/impact-of-neoadjuvant-therapy-on-eligibility-for-and-frequency-of-breast-conservation-in-stage-ii-iii-her2-positive-breast-cancer-surgical-results-of-calgb-40601-alliance
#13
Mehra Golshan, Constance T Cirrincione, William M Sikov, Lisa A Carey, Donald A Berry, Beth Overmoyer, Nora L Henry, George Somlo, Elisa Port, Harold J Burstein, Clifford Hudis, Eric Winer, David W Ollila
OBJECTIVE: It had been previously shown that patients who receive neoadjuvant systemic therapy (NST) are more likely to undergo breast-conserving therapy (BCT) than those who have primary surgery. However, the frequency with which patients who are not BCT-eligible prior to NST convert to BCT-eligible with treatment is unknown. To document this conversion rate in a subset of patients expected to have a high clinical response rate to NST, we studied surgical assessment and management of patients enrolled on a randomized neoadjuvant trial for stage II-III HER2-positive breast cancer (HER2 + BC)(CALGB 40601)...
November 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27624549/maintenance-therapy-with-decitabine-in-younger-adults-with-acute-myeloid-leukemia-in-first-remission-a-phase-2-cancer-and-leukemia-group-b-study-calgb-10503
#14
W Blum, B L Sanford, R Klisovic, D J DeAngelo, G Uy, B L Powell, W Stock, M R Baer, J E Kolitz, E S Wang, E Hoke, K Mrózek, J Kohlschmidt, C D Bloomfield, S Geyer, G Marcucci, R M Stone, R A Larson
In this prospective phase 2 clinical trial conducted by Cancer and Leukemia Group B (CALGB, now the Alliance), we studied decitabine as maintenance therapy for younger adults with acute myeloid leukemia (AML) who remained in first complete remission (CR1) following intensive induction and consolidation. Given that decitabine is clinically active in AML and with hypomethylating activity distinct from cytotoxic chemotherapy, we hypothesized that 1 year of maintenance therapy would improve disease-free survival (DFS) for AML patients <60 years, who did not receive allogeneic stem cell transplantation in CR1...
January 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/27621868/validation-of-eortc-and-calgb-prognostic-models-in-surgical-patients-submitted-to-diagnostic-palliative-or-curative-surgery-for-malignant-pleural-mesothelioma
#15
Alberto Sandri, Francesco Guerrera, Matteo Roffinella, Stefania Olivetti, Lorena Costardi, Alberto Oliaro, Pier Luigi Filosso, Paolo Olivo Lausi, Enrico Ruffini
BACKGROUND: To assess the trend of our surgical patients affected by malignant pleural mesothelioma (MPM) and submitted to diagnostic/palliative or curative surgical procedures and to validate the European Organisation for Research and Treatment of Cancer (EORTC) prognostic score in our patient population. METHODS: This is a cohort study of patients submitted to surgery for MPM from January 2007 to December 2013. Primary outcome was overall survival (OS). Univariate and multivariate-adjusted comparisons by EORTC prognostic score for OS were accomplished using Cox method...
August 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/27470602/chromosome-abnormalities-at-onset-of-complete-remission-are-associated-with-worse-outcome-in-patients-with-acute-myeloid-leukemia-and-an-abnormal-karyotype-at-diagnosis-calgb-8461-alliance
#16
Christian Niederwieser, Deedra Nicolet, Andrew J Carroll, Jonathan E Kolitz, Bayard L Powell, Jessica Kohlschmidt, Richard M Stone, John C Byrd, Krzysztof Mrózek, Clara D Bloomfield
Achievement of complete remission is essential for long-term survival of acute myeloid leukemia patients. We evaluated the prognostic significance of cytogenetics at complete remission in 258 adults with de novo acute myeloid leukemia and abnormal pre-treatment karyotypes, treated on Cancer and Leukemia Group B front-line studies, with cytogenetic data at onset of morphological complete remission. Thirty-two patients had abnormal karyotypes at time of initial complete remission. Of these, 28 had at least 1 abnormality identified pre-treatment, and 4 acute myeloid leukemia-related abnormalities not detected pre-treatment...
December 2016: Haematologica
https://www.readbyqxmd.com/read/27465221/blood-based-markers-of-efficacy-and-resistance-to-cetuximab-treatment-in-metastatic-colorectal-cancer-results-from-calgb-80203-alliance
#17
Ace J Hatch, Alexander B Sibley, Mark D Starr, J Chris Brady, Chen Jiang, Jingquan Jia, Daniel L Bowers, Herbert Pang, Kouros Owzar, Donna Niedzwiecki, Federico Innocenti, Alan P Venook, Herbert I Hurwitz, Andrew B Nixon
Circulating protein markers were assessed in patients with colorectal cancer (CRC) treated with cetuximab in CALGB 80203 to identify prognostic and predictive biomarkers. Patients with locally advanced or metastatic CRC received FOLFOX or FOLFIRI chemotherapy (chemo) or chemo in combination with cetuximab. Baseline plasma samples from 152 patients were analyzed for six candidate markers [epidermal growth factor (EGF), heparin-binding EGF (HBEGF), epidermal growth factor receptor (EGFR), HER2, HER3, and CD73]...
September 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27449492/impact-of-race-ethnicity-and-bmi-on-achievement-of-pathologic-complete-response-following-neoadjuvant-chemotherapy-for-breast-cancer-a-pooled-analysis-of-four-prospective-alliance-clinical-trials-a151426
#18
Erica T Warner, Karla V Ballman, Carrie Strand, Judy C Boughey, Aman U Buzdar, Lisa A Carey, William M Sikov, Ann H Partridge
Previous studies demonstrated poor response to neoadjuvant systemic therapy (NST) for breast cancer among black women and women who are overweight or obese, but this may be due to chemotherapy underdosing. We assessed associations of race, ethnicity, and body mass index (BMI) with pathologic complete response (pCR) in clinical trial populations. 1797 women enrolled in four NST trials (CALGB 40601, 40603; ACOSOG Z1041, Z1071) were included. Tumor subtypes were defined by estrogen receptor (ER) and HER2 status...
August 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27447359/long-term-trajectories-of-self-reported-cognitive-function-in-a-cohort-of-older-survivors-of-breast-cancer-calgb-369901-alliance
#19
Jeanne S Mandelblatt, Jonathan D Clapp, Gheorghe Luta, Leigh Anne Faul, Michelle D Tallarico, Trina D McClendon, Jessica A Whitley, Ling Cai, Tim A Ahles, Robert A Stern, Paul B Jacobsen, Brent J Small, Brandelyn N Pitcher, Estrella Dura-Fernandis, Hyman B Muss, Arti Hurria, Harvey J Cohen, Claudine Isaacs
BACKGROUND: The number of survivors of breast cancer aged ≥65 years ("older") is growing, but to the authors' knowledge, little is known regarding the cognitive outcomes of these individuals. METHODS: A cohort of cognitively intact older survivors with nonmetastatic, invasive breast cancer was recruited from 78 sites from 2004 through 2011; approximately 83.7% of the survivors (1280 survivors) completed baseline assessments. Follow-up data were collected at 6 months and annually for up to 7 years (median, 4...
July 22, 2016: Cancer
https://www.readbyqxmd.com/read/27399059/economic-evaluation-study-cheer-compliant-cost-effectiveness-analysis-of-ras-screening-for-treatment-of-metastatic-colorectal-cancer-based-on-the-calgb-80405-trial
#20
Jing Zhou, Rongce Zhao, Feng Wen, Pengfei Zhang, Ruilei Tang, Hongdou Chen, Jian Zhang, Qiu Li
Cetuximab (Cetux)/Bevacizumab (Bev) treatments have shown considerably survival benefits for patients with metastatic colorectal cancer (mCRC) in the last decade. But they are costly. Currently, no data is available on the health economic implications of testing for extended RAS wild-type (wt) prior to Cetux/Bev treatments of patients with mCRC. This paper aimed to evaluate the cost-effectiveness of predictive testing for extended RAS-wt status in mCRC in the context of targeting the use of Cetux/Bev.Markov model 1 was conducted to provide evidence evaluating the cost-effectiveness of predictive testing for KRAS-wt or extended RAS-wt status based on treatments of chemotherapy plus Cetux/Bev...
July 2016: Medicine (Baltimore)
keyword
keyword
13247
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"